Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report
Eva Moennig, Stephan Traidl Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School (MHH), Hannover, GermanyCorrespondence: Eva Moennig, Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-12-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/real-world-experience-with-tralokinumab-in-a-patient-with-recalcitrant-peer-reviewed-fulltext-article-CCID |
| _version_ | 1811196077130383360 |
|---|---|
| author | Moennig E Traidl S |
| author_facet | Moennig E Traidl S |
| author_sort | Moennig E |
| collection | DOAJ |
| description | Eva Moennig, Stephan Traidl Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School (MHH), Hannover, GermanyCorrespondence: Eva Moennig, Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School (MHH), Carl-Neuberg-Str.1, Hannover, 30625, Germany, Email moennig.eva@mh-hannover.deAbstract: Atopic dermatitis (AD) is a common inflammatory skin disease, which negatively impacts the individual’s quality of life (QoL). In particular, moderate-to-severe AD is frequently difficult to treat. We report a case involving a 40-year-old male who has suffered from AD since early childhood and who also had co-morbid seasonal allergic rhinitis. In June 2021, we initiated treatment with the fully human IgG4 monoclonal antibody tralokinumab that specifically targets IL-13 and the patient has been followed for 38 weeks. During this time period, he received a booster vaccination for COVID-19 (week 18) and developed the disease in April 2022 (both with minimal impact). Tralokinumab treatment reduced AD symptoms, was well tolerated and improved QoL scores, and the patient reported that he was very satisfied with the treatment.Keywords: atopic dermatitis, COVID-19, systemic therapy, tralokinumab |
| first_indexed | 2024-04-12T00:52:31Z |
| format | Article |
| id | doaj.art-7aed8c7a575545bb8162ea8be2a1959d |
| institution | Directory Open Access Journal |
| issn | 1178-7015 |
| language | English |
| last_indexed | 2024-04-12T00:52:31Z |
| publishDate | 2022-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj.art-7aed8c7a575545bb8162ea8be2a1959d2022-12-22T03:54:42ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152022-12-01Volume 152825283080479Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case ReportMoennig ETraidl SEva Moennig, Stephan Traidl Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School (MHH), Hannover, GermanyCorrespondence: Eva Moennig, Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School (MHH), Carl-Neuberg-Str.1, Hannover, 30625, Germany, Email moennig.eva@mh-hannover.deAbstract: Atopic dermatitis (AD) is a common inflammatory skin disease, which negatively impacts the individual’s quality of life (QoL). In particular, moderate-to-severe AD is frequently difficult to treat. We report a case involving a 40-year-old male who has suffered from AD since early childhood and who also had co-morbid seasonal allergic rhinitis. In June 2021, we initiated treatment with the fully human IgG4 monoclonal antibody tralokinumab that specifically targets IL-13 and the patient has been followed for 38 weeks. During this time period, he received a booster vaccination for COVID-19 (week 18) and developed the disease in April 2022 (both with minimal impact). Tralokinumab treatment reduced AD symptoms, was well tolerated and improved QoL scores, and the patient reported that he was very satisfied with the treatment.Keywords: atopic dermatitis, COVID-19, systemic therapy, tralokinumabhttps://www.dovepress.com/real-world-experience-with-tralokinumab-in-a-patient-with-recalcitrant-peer-reviewed-fulltext-article-CCIDatopic dermatitiscovid-19systemic therapytralokinumab |
| spellingShingle | Moennig E Traidl S Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report Clinical, Cosmetic and Investigational Dermatology atopic dermatitis covid-19 systemic therapy tralokinumab |
| title | Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report |
| title_full | Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report |
| title_fullStr | Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report |
| title_full_unstemmed | Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report |
| title_short | Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report |
| title_sort | real world experience with tralokinumab in a patient with recalcitrant atopic dermatitis a case report |
| topic | atopic dermatitis covid-19 systemic therapy tralokinumab |
| url | https://www.dovepress.com/real-world-experience-with-tralokinumab-in-a-patient-with-recalcitrant-peer-reviewed-fulltext-article-CCID |
| work_keys_str_mv | AT moennige realworldexperiencewithtralokinumabinapatientwithrecalcitrantatopicdermatitisacasereport AT traidls realworldexperiencewithtralokinumabinapatientwithrecalcitrantatopicdermatitisacasereport |